DavidAGoldfarbMD

Professor, Urology, Cleveland Clinic Lerner College of Medicine

Dr. Goldfarb is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011, 2013
Top MD Consumers Checkbook
Fellow (FACS) American College of Surgeons

PubMed

603 citations
The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease.
Jonathan M. Shillingford, Noel S. Murcia, Claire H. Larson, Seng Hui Low, Ryan C. Hedgepeth
Proceedings of the National Academy of Sciences of the United States of America. 2006-04-04
315 citations
Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine.
Stuart M. Flechner, David A. Goldfarb, Charles S. Modlin, Jingyuan Feng, Venkatesh Krishnamurthi
Transplantation. 2002-10-27
143 citations
Demographic and clinical characteristics associated with glomerular filtration rates in living kidney donors
Emilio D. Poggio, Andrew D. Rule, Roberto Tanchanco, Susana Arrigain, Robert S. Butler
Kidney International. 2009-05-02

Journal Articles

Dramatic Secular Changes in Prognosis for Kidney Transplant Candidates in the United States
Stuart M Flechner, John R Sedor, David A Goldfarb, Emilio D Poggio, American journal of transplantation